Safety and Efficacy of Empagliflozin on Heart Failure Dialysis Patients
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- Brain Natriuretic Peptide
研究概览
简要总结
Empagliflozin is not still approved for glomerular filtration rate < 20 cc/min/1.73m2. Considering the cardiac and renal benefits of this drug, the evaluation of the safety and efficacy of Empagliflozin for heart failure dialysis patients seems to be mandatory.
详细描述
Heart failure dialysis patients with residual renal function will be followed up on Empagliflozin based on echocardiographic parameters, pro-brain natriuretic peptide levels, diuresis volume, and serum acidity.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Heart failure on dialysis with residual renal function
排除标准
- •Dialysis patients with no residual urine
研究组 & 干预措施
Empagliflozin
Heart failure dialysis patients will be treated with Empagliflozin
干预措施: Empagliflozin10Mg Tab (Drug)
结局指标
主要结局
Brain Natriuretic Peptide
时间窗: one month after administration
serum level
次要结局
未报告次要终点
研究者
nooshin dalili
Assistant Professor
Shahid Beheshti University of Medical Sciences
